In a major success, Nestle has won over the nod of Aimmune Therapeutics shareholders for acquiring the full ownership of the peanut allergy treatment, approved by the US. The value of the deal is worth $ 2 billion.
After the acquisition, Nestle would have a market expansion in a totally different dimension from the FMCG sector. Following the coronavirus pandemic, the launch of the treatment got dragged for months.
Notably, the company held accounts of around eight four per cent of outstanding shares. The cost per share stands at $34.50 (until expiration date). As per Nestle, the minimum condition for consummation has been satisfied.